<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03852940</url>
  </required_header>
  <id_info>
    <org_study_id>CHD085-12</org_study_id>
    <nct_id>NCT03852940</nct_id>
  </id_info>
  <brief_title>Impact of Early Enteral vs. Parenteral Nutrition on Preservation of Gut Mucosa Integrity in Patients Requiring Mechanical Ventilation and Catecholamine</brief_title>
  <official_title>Impact of Early Enteral vs. Parenteral Nutrition on Preservation of Gut Mucosa Integrity in Patients Requiring Mechanical Ventilation and Catecholamines: an Ancillary Study of the NUTRIREA2 Trial (NCT01802099)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that a strategy involving early first-line enteral nutrition is associated
      with improved preservation of gut mucosa integrity, as assessed based on the plasma
      citrulline level at H72, compared to a strategy involving early first-line parenteral
      nutrition
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Published data suggest that enteral nutrition may be associated with improved preservation of
      the gut lymphoid tissues and gut immune function, as well as with decreased gut mucosa
      permeability, thereby diminishing the risk of organ failure. Citrulline is an amino acid
      produced from glutamine by small-bowel enterocytes. Plasma citrulline levels reflect
      functional enterocyte mass. Intestinal fatty acid-binding protein (I-FABP, also known as
      FABP2) is a small protein found in the cytosol of small-bowel enterocytes. Plasma I-FABP is
      normally undetectable and, when elevated, constitutes a reliable marker for enterocyte
      damage. The hypothesis underlying this ancillary study is that first-line enteral nutrition
      is associated with improved gut mucosa integrity and function compared to parenteral
      nutrition.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Data Safety and Monitoring Board 's request
  </why_stopped>
  <start_date type="Actual">January 27, 2015</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 7, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma citrulline level</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>first week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma levels of citrulline</measure>
    <time_frame>Day 0, Day 3, Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>I-FABP</measure>
    <time_frame>Day 0, Day 3, Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients whose plasma I-FABP is ≥100 pg/mL</measure>
    <time_frame>Day 0, Day 3, Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients whose plasma citrulline is ≤10 μL/L</measure>
    <time_frame>Day 0, Day 3, Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean plasma I-FABP</measure>
    <time_frame>Day 0, Day 3, Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean plasma citrulline</measure>
    <time_frame>Day 0, Day 3, Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with at least one episode of bacteremia</measure>
    <time_frame>until discharge from ICU (average: 10 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with at least one episode of gastrointestinal intolerance</measure>
    <time_frame>until discharge from ICU (average: 10 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with at least one episode of diarrhea</measure>
    <time_frame>until discharge from ICU (average: 10 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Acute Respiratory Failure</condition>
  <condition>Shock</condition>
  <arm_group>
    <arm_group_label>Parenteral nutrition</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level &lt; 2 mmol/l). After Day 7, all patients will be fed via the enteral route.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enteral nutrition</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Parenteral nutrition</intervention_name>
    <arm_group_label>Parenteral nutrition</arm_group_label>
    <other_name>Intravenous nutrition</other_name>
    <other_name>intravenous feeding</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Enteral Nutrition</intervention_name>
    <arm_group_label>Enteral nutrition</arm_group_label>
    <other_name>Enteral feeding</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Invasive mechanical ventilation expected to be required more than 48 hours

          -  Nutrition started within 24 hours after initiation of endotracheal mechanical
             ventilation

          -  Treatment with vasoactive drug administered via a central venous catheter

          -  Age over 18 years

          -  Signed information

        Exclusion Criteria:

          -  Abdominal surgery within 1 month before inclusion

          -  History of esophageal, gastric, duodenal or pancreatic surgery

          -  Bleeding from the esophagus, stomach or bowel

          -  enteral nutrition via gastrostomy or jejunostomy

          -  pregnancy

          -  Treatment-limitation decisions

          -  Current inclusion in a trial on comparison between enteral and parenteral nutrition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean REIGNIER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD Vendee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier d'Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Dieppe</name>
      <address>
        <city>Dieppe</city>
        <zip>76202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>February 22, 2019</last_update_submitted>
  <last_update_submitted_qc>February 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vasoactive drug</keyword>
  <keyword>mechanical ventilation</keyword>
  <keyword>early enteral nutrition</keyword>
  <keyword>intensive care unit</keyword>
  <keyword>early parenteral nutrition</keyword>
  <keyword>critical care medicine</keyword>
  <keyword>nosocomial infection</keyword>
  <keyword>mortality</keyword>
  <keyword>shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

